Medical Cannabis

More Tonnes, Tougher Economics: Europe’s Medical Cannabis Outlook for 2027

Written for Business of Cannabis by Oskar Fletcher, Chief Executive of pharmaceutical contract manufacturing operator Blossom Pharma.

Written for Business of Cannabis by Oskar Fletcher, Chief Executive of pharmaceutical contract manufacturing operator Blossom Pharma.

As Germany’s medical cannabis import figures arrive, the industry’s attention inevitably turns to growth. How much flower entered the country? Which trading partners gained share? Does the latest quarter justify a more ambitious forecast?

Those are useful questions. But for businesses planning for 2027, they are only the beginning.

My expectation is that Europe’s medical cannabis opportunity will continue to expand, while the commercial demands on suppliers become more exacting. Increasing volumes will create opportunities. They will also test pricing, working capital and the ability to supply consistent products repeatedly.

The defining feature of 2027 could be a widening gap between volume growth and financial performance. The business failures we have seen in recent months are already a warning: more product moving through the market will not automatically mean more profitable businesses.

Read beyond the import headline

The scale of the market’s expansion is substantial. ABDA’s 2026 statistical report, drawing on BfArM figures, records German cannabis imports for medical and scientific purposes rising from approximately 72.9 tonnes in 2024 to 201.1 tonnes in 2025, an increase of around 176%. These figures cover flower and extracts, rather than patient dispensing. 

That establishes the scale of supply growth. It does not establish how much product reached patients, how quickly inventories turned or whether suppliers earned an acceptable return.

A shipment may support current orders, replenish inventory or anticipate future demand. Imports therefore need to be read alongside other indicators.

For 2027, I would put repeat ordering alongside import growth as a measure of commercial progress. An initial shipment demonstrates that a supply route can operate. Consistent reorders provide stronger evidence that a product has found a sustainable place in the market.

Across the same period in 2025 and 2026, Blossom’s actual flower shipments to European markets increased by approximately 35%. Our experience offers one operational perspective, rather than a proxy for the whole market. Its value lies in understanding what sits beneath the headline: whether customers are returning, whether demand is broadening and whether delivery schedules are becoming more predictable.

My expectation is that purchasing will become more selective in 2027. Buyers managing broader product ranges and pressure on prices will have stronger reasons to prioritise products that sell consistently. Suppliers should prepare for closer scrutiny of reorder rates, stock availability and the commercial purpose of each new product.

Growth must survive the price conversation

The second question is what increasing supply means for commercial viability.

On a comparable product basis, we have seen the average wholesale price for Germany fall by approximately 26% over the past 12 months.

That creates a demanding growth equation. As a simple illustration, a business selling 35% more product at a realised price 26% lower would generate almost exactly the same product revenue, before considering costs or changes in mix. 

Nevertheless, it explains why shipment growth alone can give an incomplete picture of business health.

Lower flower prices can improve affordability. They can also expose business models that depend on a premium customers are no longer willing to pay.

My expectation for 2027 is continued pricing pressure on readily substitutable flower, with greater variation between product segments. Some products may retain a premium through consistent quality, established demand and reliable availability. Novelty alone will become harder to defend commercially.

A procurement decision based principally on the quoted price per gram can also overlook costs that emerge later. Additional testing, documentation problems, delays, rejected material and inconsistent specifications all affect the economics of the finished product.

The relevant comparison is the cost of supplying a compliant product consistently, within the time required.

Any discussion of pricing must also distinguish the stages of the supply chain. A bulk flower quote and a pharmacy selling price cover different products, services, costs and risks. The difference between them cannot simply be described as profit.

The constructive question for 2027 is where businesses can remove avoidable cost while preserving the quality and continuity patients need.

A wider sourcing map raises the importance of evidence

The sourcing picture is already international but remains concentrated. ABDA’s BfArM-sourced table records approximately 93 tonnes of German imports from Canada and 55.2 tonnes from Portugal in 2025. Together, those two reported countries accounted for almost 74% of the total.

Those trade figures should not automatically be read as a map of cultivation. Material can move through processing and export hubs before reaching its destination. Understanding where a product was grown, processed and released requires a more detailed view of its supply chain.

For companies considering supply from Thailand, South America or other emerging origins, a competitive cultivation price is a starting point. Commercial viability also depends on the quality of the material, the supporting records and the requirements of the intended manufacturing and destination-market route.

The industry should resist broad assumptions about quality based on geography. It should be equally cautious about assuming that a later processing step can resolve every weakness in the material or its production history.

The standard should be evidence: what happened to this batch, how was it controlled and can the relevant parties substantiate its suitability?

My prediction is that supplier qualification will become a more important commercial dividing line in 2027. A wider sourcing network offers resilience only when the material and documentation meet the requirements of the intended route.

That is why the discussion around EU-GMP processing matters. Clear expectations and well-supported qualification decisions give responsible suppliers a stronger basis on which to invest. They also help buyers assess competing offers on more than price.

Europe’s growth will take different forms

Germany will remain central to many companies’ European plans, but the opportunity extends beyond it.

In the UK, Business of Cannabis’s analysis of Home Office information puts unlicensed cannabis flower imports at approximately 30.1 tonnes in 2025, compared with 15 tonnes in 2024. Its analysis of separate NHS Business Services Authority data reports approximately 1.7 million privately prescribed unlicensed cannabis items dispensed through English community pharmacies in 2025, up from around 669,000 in 2024. Prescription items are not unique patients, and the dispensing figure includes products beyond flower. 

These are different measures, but both underline the need to plan for meaningful scale outside Germany.

They do not justify treating Europe as a single market with a single growth trajectory. Demand, product requirements and commercial conditions need to be understood country by country.

For 2027, I expect successful expansion to depend increasingly on choosing the right products and partners for each destination. Adding countries to a distribution map will matter less than establishing a repeatable business in each one.

Regulatory developments will remain an important variable. Growth plans should therefore be tested against changes in access and prescribing conditions, alongside pressure on prices and slower inventory movement.

Build the 2027 plan around dependable supply

These pressures will also make working capital more important.

A lower procurement price offers limited comfort if a business holds stock for longer, waits longer for payment or has to replace unsuitable material. Volume growth can increase the cash required to operate before it improves profitability.

I expect buyers to concentrate more of their repeat business with suppliers that demonstrate consistent execution. That could support closer commercial partnerships and consolidation, although higher volumes alone will not determine which businesses succeed.

At Blossom, we see our role as connecting global supply with the practical requirements of European markets. That means bringing processing, packaging, quality oversight and distribution planning into the commercial conversation early, so that an attractive sourcing opportunity can become a dependable supply programme.

Our view for 2027 is optimistic. We expect further opportunities for businesses that combine competitive economics with reliable execution. We also expect a more demanding market in which quality, delivery and cash discipline receive greater scrutiny.

When the next BfArM figures arrive, the headline volume will deserve attention. The more revealing question will be what that supply enables: dependable availability, sustainable commercial relationships and better access for patients.

The industry’s next year should be judged by how consistently it delivers those outcomes.

Oskar Fletcher

More from Oskar

Spotted an error, or have a tip? Contact the newsroom.

Up next · Medical Cannabis

Notes from a Scaling Healthcare Business: Governance First

BusinessOfCannabis · 10 November 2026

More